(Reuters) – The College of Oxford has launched a examine to evaluate the security and immune response of the COVID-19 vaccine it has developed with AstraZeneca Plc in kids for the primary time, it mentioned on Saturday.
The brand new mid-stage trial will decide whether or not the vaccine is efficient on folks between the ages of 6 and 17, based on an emailed assertion from the college.
Round 300 volunteers might be enrolled and first inoculations are anticipated this month, Oxford mentioned.
The 2-dose Oxford/AstraZeneca vaccine has been hailed as a “vaccine for the world” as a result of it’s cheaper and simpler to distribute than some rivals.
AstraZeneca has a goal to supply three billion doses this yr and goals to supply over 200 million doses per thirty days by April.
A HuffPost Information To Coronavirus
As COVID-19 instances rise, it’s extra vital than ever to stay linked and knowledgeable. Be a part of the HuffPost neighborhood right now. (It’s free!)
